Journal: eLife

Article Title: Self-establishing communities enable cooperative metabolite exchange in a eukaryote

doi: 10.7554/eLife.09943

Figure Lengend Snippet: Strains and plasmids used in this study. DOI: http://dx.doi.org/10.7554/eLife.09943.020

Article Snippet: pFS118 , Yeast high-copy vector with endogenous promoter for ura4 + (Addgene number: 12378) , ( ) .

Techniques: Derivative Assay, Dissection, Knock-Out, Plasmid Preparation, Marker

Journal: RSC Advances

Article Title: Implementation of a dynamic intestinal gut-on-a-chip barrier model for transport studies of lipophilic dioxin congeners †

doi: 10.1039/c8ra05430d

Figure Lengend Snippet: The predicted log P values of dioxin congeners, 25 and limit of quantification (LOQ) by GC-HRMS

Article Snippet: The dioxin mixtures were obtained from Cambridge Isotope Laboratories, Inc. (Tewksbury, USA) and contained 10 PCDF congeners: 2,3,7,8-TCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 2,3,4,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,4,6,7,8-HpCDF, 1,2,3,4,7,8,9-HpCDF and OCDF, and 7 PCDD congeners: 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 1,2,3,4,6,7,8-HpCDD and OCDD.

Techniques:

Journal: RSC Advances

Article Title: Implementation of a dynamic intestinal gut-on-a-chip barrier model for transport studies of lipophilic dioxin congeners †

doi: 10.1039/c8ra05430d

Figure Lengend Snippet: Mass balance from dioxin transport experiments analysed by GC-HRMS ( n = 3)

Article Snippet: The dioxin mixtures were obtained from Cambridge Isotope Laboratories, Inc. (Tewksbury, USA) and contained 10 PCDF congeners: 2,3,7,8-TCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 2,3,4,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,4,6,7,8-HpCDF, 1,2,3,4,7,8,9-HpCDF and OCDF, and 7 PCDD congeners: 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 1,2,3,4,6,7,8-HpCDD and OCDD.

Techniques:

Journal: RSC Advances

Article Title: Implementation of a dynamic intestinal gut-on-a-chip barrier model for transport studies of lipophilic dioxin congeners †

doi: 10.1039/c8ra05430d

Figure Lengend Snippet: Comparison of dioxin congeners in the cellular fraction and transported over the cell barrier between a dynamic ( ) versus a static ( ) model. (A) Transport of dioxin congeners through the monolayer of cells cultured in chips and Transwells given as a percentage (±SEM) of dioxin congeners in the basal side compared to the total exposed amount. (B) Fraction of dioxin congeners in the cell fraction given as a percentage (±SEM) of dioxin congeners in the cellular fraction compared to the total exposed amount. (C) Correlation between transported dioxin congeners in the dynamic versus static model. (D) Correlation between dioxin congeners in the cellular fraction in the dynamic versus static model, 1 = OCDF; 2 = 1,2,3,4,7,8,9-HpCDF; 3 = 1,2,3,4,6,7,8-HpCDD; 4 = OCDD; 5 = 1,2,3,4,7,8-HxCDD; 6 = 1,2,3,4,7,8-HxCDF; 7 = 1,2,3,4,6,7,8-HpCDF; 8 = 1,2,3,7,8,9-HxCDF; 9 = 2,3,4,6,7,8-HxCDF; 10 = 2,3,4,7,8-PeCDF; 11 = 1,2,3,7,8,9-HxCDD; 12 = 1,2,3,6,7,8-HxCDF; 13 = 1,2,3,6,7,8-HxCDD; 14 = 1,2,3,7,8-PeCDD; 15 = 2,3,7,8-TCDD; 16 = 2,3,7,8-TCDF; 17 = 1,2,3,7,8-PeCDF.

Article Snippet: The dioxin mixtures were obtained from Cambridge Isotope Laboratories, Inc. (Tewksbury, USA) and contained 10 PCDF congeners: 2,3,7,8-TCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 2,3,4,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,4,6,7,8-HpCDF, 1,2,3,4,7,8,9-HpCDF and OCDF, and 7 PCDD congeners: 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 1,2,3,4,6,7,8-HpCDD and OCDD.

Techniques: Cell Culture

Journal: RSC Advances

Article Title: Implementation of a dynamic intestinal gut-on-a-chip barrier model for transport studies of lipophilic dioxin congeners †

doi: 10.1039/c8ra05430d

Figure Lengend Snippet: Experimental and predicted values of endpoint for each developed model, the training (◊) and validation set (■). 1 = 1,2,3,7,8,9-HxCDD; 2 = 1,2,3,6,7,8-HxCDD; 3 = 1,2,3,6,7,8-HxCDF; 4 = 1,2,3,4,6,7,8-HpCDF; 5 = 1,2,3,7,8-PeCDF; 6 = 2,3,7,8-TCDF; 7 = 1,2,3,7,8,9-HxCDF; 8 = 2,3,7,8-TCDD; 9 = 1,2,3,7,8-PeCDD; 10 = 2,3,4,6,7,8-HxCDF; 11 = 2,3,4,7,8-PeCDF; 12 = 1,2,3,4,6,7,8-HpCDD; 13 = 1,2,3,4,7,8-HxCDF; 14 = 1,2,3,4,7,8,9-HpCDF; 15 = OCDF; 16 = 1,2,3,4,7,8-HxCDD; 17 = OCDD.

Article Snippet: The dioxin mixtures were obtained from Cambridge Isotope Laboratories, Inc. (Tewksbury, USA) and contained 10 PCDF congeners: 2,3,7,8-TCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8-PeCDF, 1,2,3,4,7,8-HxCDF, 1,2,3,6,7,8-HxCDF, 2,3,4,6,7,8-HxCDF, 1,2,3,7,8,9-HxCDF, 1,2,3,4,6,7,8-HpCDF, 1,2,3,4,7,8,9-HpCDF and OCDF, and 7 PCDD congeners: 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 1,2,3,4,7,8-HxCDD, 1,2,3,6,7,8-HxCDD, 1,2,3,7,8,9-HxCDD, 1,2,3,4,6,7,8-HpCDD and OCDD.

Techniques:

Journal: Genome Medicine

Article Title: A novel spliceosomopathy caused by de novo SF3B3 variants

doi: 10.1186/s13073-026-01610-4

Figure Lengend Snippet: SF3B3 mRNA expression and protein levels of SF3B1-4, SF3B6, PHF5A, and RNF113A in patient-derived and control fibroblasts. ( A ) Representative immunoblots of whole cell lysates from subject (P1, P2, P6 and P8) and control (C1-3) fibroblast cultures. Levels of the investigated proteins were monitored with the indicated antibodies. Band intensity was quantified using ChemiDoc MP imaging system. SF3B3, SF3B1-2, SF3B4, SF3B6, PHF5A, and RNF113A protein levels were normalized to GAPDH used as loading control. ( B ) Histograms showing the relative amount of SF3B3 (mean ± SD of four experiments), SF3B1-2 and 4 (mean ± SD of three experiments), SF3B6 and RNF113A (mean ± SD of five experiments) and PHF5A (mean ± SD of 6 experiments); t test (two-tailed, homoscedastic): * p < 0.05, ** p < 0.01, *** p < 0.001. ( C ) Histogram showing the expression level of SF3B3 mRNA, assessed by qRT-PCR, in the patients’ fibroblast cell lines compared with controls ( n = 3; t test (two-tailed, homoscedastic); ns: non-significant). GAPDH was used as the housekeeping gene for normalization

Article Snippet: The following primary antibodies were employed: rabbit polyclonal anti-SF3B3 (A302-508 A, Bethyl Laboratories), rabbit polyclonal anti-SF3B1 (27684-1-AP, Proteintech), rabbit polyclonal anti-SF3B2 (10919-1-AP, Proteintech), rabbit polyclonal anti-SF3B4 (A303-950 A, Bethyl Laboratories), rabbit polyclonal anti-SF3B14 (SF3B6) (12378-1-AP, Proteintech), rabbit polyclonal anti-PHF5A (15554-1-AP, Proteintech), rabbit polyclonal anti-RNF113A (27018-1-AP, Proteintech), mouse monoclonal anti-GAPDH (0411) (sc-47724, Santa Cruz Biotechnology Inc).

Techniques: Expressing, Derivative Assay, Control, Western Blot, Imaging, Two Tailed Test, Quantitative RT-PCR